These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 32213685)
21. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer. Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083 [TBL] [Abstract][Full Text] [Related]
22. Factors affecting the negative predictive value of positron emission tomography/computed tomography for axillary lymph node staging in breast cancer patients. Kim J; Cho H; Gwak G; Yang K; Kim JY; Shin YJ; Seo YY; Park I Asian J Surg; 2020 Jan; 43(1):193-200. PubMed ID: 30914155 [TBL] [Abstract][Full Text] [Related]
23. Discordant results in Parisse-Di Martino S; Faure C; Mognetti T Cancer Treat Res Commun; 2021; 27():100344. PubMed ID: 33636590 [TBL] [Abstract][Full Text] [Related]
24. FDG-PET for axillary lymph node staging in primary breast cancer. Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635 [TBL] [Abstract][Full Text] [Related]
25. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer. Fujii T; Yajima R; Tatsuki H; Kuwano H Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160 [TBL] [Abstract][Full Text] [Related]
26. A prospective comparative study of contrast-enhanced CT, contrast-enhanced MRI and 18F-FDG PET/CT in the preoperative staging of colorectal cancer patients. Guney IB; Teke Z; Kucuker KA; Yalav O Ann Ital Chir; 2020; 91():658-667. PubMed ID: 32213686 [TBL] [Abstract][Full Text] [Related]
27. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. Fuster D; Duch J; Paredes P; Velasco M; Muñoz M; Santamaría G; Fontanillas M; Pons F J Clin Oncol; 2008 Oct; 26(29):4746-51. PubMed ID: 18695254 [TBL] [Abstract][Full Text] [Related]
28. The new perspective of PET/CT for axillary nodal staging in early breast cancer patients according to ACOSOG Z0011 trial PET/CT axillary staging according to Z0011. Kong E; Choi J Nucl Med Commun; 2021 Dec; 42(12):1369-1374. PubMed ID: 34392296 [TBL] [Abstract][Full Text] [Related]
29. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. Pritchard KI; Julian JA; Holloway CM; McCready D; Gulenchyn KY; George R; Hodgson N; Lovrics P; Perera F; Elavathil L; O'Malley FP; Down N; Bodurtha A; Shelley W; Levine MN J Clin Oncol; 2012 Apr; 30(12):1274-9. PubMed ID: 22393089 [TBL] [Abstract][Full Text] [Related]
30. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT. Monzawa S; Adachi S; Suzuki K; Hirokaga K; Takao S; Sakuma T; Hanioka K Ann Nucl Med; 2009 Dec; 23(10):855-61. PubMed ID: 19876704 [TBL] [Abstract][Full Text] [Related]
31. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging. Taira N; Ohsumi S; Takabatake D; Hara F; Takashima S; Aogi K; Takashima S; Inoue T; Sugata S; Nishimura R Jpn J Clin Oncol; 2009 Jan; 39(1):16-21. PubMed ID: 18997183 [TBL] [Abstract][Full Text] [Related]
32. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients. Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417 [TBL] [Abstract][Full Text] [Related]
33. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796 [TBL] [Abstract][Full Text] [Related]
34. Breast cancer staging in a single session: whole-body PET/CT mammography. Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831 [TBL] [Abstract][Full Text] [Related]
35. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629 [TBL] [Abstract][Full Text] [Related]
36. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439 [TBL] [Abstract][Full Text] [Related]
37. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Kumar R; Zhuang H; Schnall M; Conant E; Damia S; Weinstein S; Chandra P; Czerniecki B; Alavi A Nucl Med Commun; 2006 Mar; 27(3):231-6. PubMed ID: 16479242 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Barranger E; Grahek D; Antoine M; Montravers F; Talbot JN; Uzan S Ann Surg Oncol; 2003 Jul; 10(6):622-7. PubMed ID: 12839846 [TBL] [Abstract][Full Text] [Related]
39. The predictive value, sensitivity, specificity, and accuracy of PET CT in the evaluation of axillary metastases in breast cancer. Cetindag Ö; Avsar G; Hakseven M; Deryol R; Ertekin SÇ; Karasoy D; Eroglu A; Bayar S Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10008-10015. PubMed ID: 37916371 [TBL] [Abstract][Full Text] [Related]
40. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases. Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]